Today, Capricor Therapeutics announced positive five-year data from the company’s ongoing HOPE-2 open label extension (OLE) study of Deramiocel, Capricor’s novel cell therapy, in individuals living with Duchenne.

According to Capricor, among the nine patients who remain enrolled in the HOPE-2 OLE study, treatment with Deramiocel continued to attenuate disease progression over five years, as measured by Performance of the Upper Limb (PUL 2.0). Cardiac function, as measured by left ventricular ejection fraction (LVEF) on cardiac MRI, remained stable over the full five-year period, in contrast to the modeled decline of approximately 3.2% per year observed in a propensity-matched external cardiac comparator. Capricor indicated that Deramiocel continued to demonstrate a favorable safety profile throughout the study. 

Capricor will be presenting the five-year data from the HOPE-2 open label extension (OLE) study of Deramiocel at PPMD’s 2026 Annual Conference during a late breaking news session on Saturday, June 27, at 4:10 PM ET. This session will be recorded and made available to the public as soon as possible within two weeks of the live event.

Dr. Chet Villa, from Cincinnati Children’s Hospital, also presented previously reported results from the HOPE-3 Phase 3 trial of Deramiocel at PPMD’s 2026 Annual Conference during the “The Heart of the Matter: A Cardiac Care Panel” session, on Friday, June 26. This session is recorded and will be made available to the public as soon as possible within two weeks of the live event.

Read Capricor’s press release here.